In a report released yesterday, Salim Syed from Mizuho Securities maintained a Hold rating on Amgen (AMGN – Research Report), with a price target of $208.00. The company’s shares closed last Friday at $246.25.
According to TipRanks, Syed is an analyst with an average return of -13.4% and a 38.10% success rate. Syed covers the Healthcare sector, focusing on stocks such as Cytokinetics, Atara Biotherapeutics, and BridgeBio Pharma.
In addition to Mizuho Securities, Amgen also received a Hold from BMO Capital’s Evan Seigerman in a report issued on August 5. However, on the same day, Piper Sandler maintained a Buy rating on Amgen (NASDAQ: AMGN).
See the top stocks recommended by analysts >>
AMGN market cap is currently $131.5B and has a P/E ratio of 20.87.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1980, California-based Amgen, Inc. is one of the world’s leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
Read More on AMGN:
- Analysts Are Bullish on These Technology Stocks: Ansys (ANSS), Spirit AeroSystems (SPR)
- Credit Suisse Reaffirms Their Hold Rating on Mayne Pharma Group Limited (MAYNF)
- Appen Ltd. (APPEF) Receives a Hold from Citigroup
- HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer
- Mizuho Securities Keeps Their Hold Rating on Neurocrine (NBIX)
